Dental endosseous implants in patients on bisphosphonate therapy

Implant Dentistry

Volumn 15, Issue 3, 2006, Pages 212-218

  Scully, Crispian ^a   Madrid, Carlos ^b,c   Bagan, Jose ^d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Department of Oral Medicine Oral Surgery and Dental Care

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d University Hospital   (Spain)

Author keywords

Bone disorders; Hormone replacement therapy; Implants; Osteochemonecrosis; Osteonecrosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ARTICLE; BONE NECROSIS; CHEMICALLY INDUCED DISORDER; DRUG CONTRAINDICATION; HUMAN; JAW DISEASE; TOOTH IMPLANTATION;

BONE DENSITY CONSERVATION AGENTS; DENTAL IMPLANTATION, ENDOSSEOUS; DIPHOSPHONATES; HUMANS; JAW DISEASES; OSTEONECROSIS;

EID: 33748707578     PISSN: 10566163     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.id.0000236120.22719.02     Document Type: Article

References (40)

1. Beikler T, Flemmig TF. Implants in the medically compromised patient. Crit Rev Oral Biol Med. 2003; 14:305-316.
2. Scully C, Dios PD, Hobkirk J. Dental implants in the medically compromised patient. J Oral Rehab. In press.
3. Dao TT, Anderson JD, Zarb GA. Is osteoporosis a risk factor for osseointegration of dental implants? Int J Oral Maxillofac Implants. 1993;8:137-144.
4. Cooper LF. Systemic effectors of alveolar bone mass and implications in dental therapy. Periodontol 2000. 2000;23:103-109.
5. Minsk L, Polson AM. Dental implant outcomes in postmenopausal women undergoing hormone replacement. Compend Contin Educ Dent. 1998; 19:859-862, 864.
6. Starck WJ, Epker BN. Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: A case report. Int J Oral Maxillofac Implants. 1995;10:74-78.
7. Friberg B, Ekestubbe A, Mellstrom D, et al. Brånemark implants and osteoporosis: A clinical exploratory study. Clin Implant Dent Relat Res. 2001;3:50-56.
8. Friberg B. Treatment with dental implants in patients with severe osteoporosis: A case report. Int J Periodontics Restorative Dent. 1994;14:348-353.
9. Eder A, Watzek G. Treatment of a patient with severe osteoporosis and chronic polyarthritis with fixed implant-supported prosthesis: A case report. Int J Oral Maxillofac Implants. 1999;14:587-590.
10. Simon Z, Watson PA. Biomimetic dental implants-New ways to enhance osseointegration. J Can Dent Assoc. 2002; 68:286-288.
11. Gonzalez-Moles MA, Bagan-Sebastian JV. Alendronate-related oral mucosa ulcerations. J Oral Pathol Med. 2000;29:514-518.
12. Demerjian N, Bolla G, Spreux A. Severe oral ulcerations induced by alendronate. Clin Rheumatol. 1999; 18:349-350.
13. Weinberg MA. Bisphosphonate-associated osteonecrosis of the jaws: Impact on oral health. US Pharm. 2006;5: 62-69.
14. Bagan JV, Jimenez Y, Murillo J, et al. Jaw osteonecrosis associated with bisphosphonates: Multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol. 2006;42: 327-329
15. Merigo E, Manfredi M, Meleti M, et al. Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): A four-case report. J Oral Pathol Med. 2005;34:613-617.
16. Marx RE, Sawatari Y, Forth M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567-1575.
17. Hellstein JW, Marek CL Bisphos-phonate induced osteochemonecrosis of the jaws: An ounce of prevention may be worth a pound of cure. Spec Care Dentist. 2006;26:8-12.
18. Migliorati CA, Casiglia J, Epstein J, et al. Managing the care of patients with bisphosphonate-associated osteonecrosis: An American Academy of Oral Medicine position paper. J Am Dent Assoc. 2005:136: 1658-1668.
19. Migliorati CA, Schubert MM, Peterson DE, et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: An emerging oral complication of supportive cancer therapy. Cancer. 2005:104:83-93.
20. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with chemotherapy. J Oral Maxillofac Surg. 2003:61:1104-1107.
21. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg. 2003:61:1115-1117.
22. Woo SB, Hellstein JW, Kalmar JR. Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006:144:753-761.
23. Migliorati CA. Bisphosphonate-associated oral osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;99:135.
24. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol. 2005; 23:8580-8587.
25. Gibbs SD, O'Grady J, Seymour JF, et al. Bisphosphonate-induced osteonecrosis of the jaw requires early detection and intervention. Med J Aust. 2005:183:549-550.
26. Melo MD, Obeid G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: Strategies for prevention and early recognition. J Am Dent Assoc. 2005;136: 1675-1681.
27. Purcell PM, Boyd IW. Bisphosphonates and osteonecrosis of the jaw. Med J Aust. 2005:182:417-418.
28. Yeo AC, Lye KW, Poon CY. Bisphosphonate-related osteonecrosis of the jaws. Singapore Dent J. 2005;27:36-40.
29. Marunick M, Miller R, Gordon S. Adverse oral sequelae to bisphosphonate administration. J Mich Dent Assoc. 2005; 87:44-49.
30. Lenz JH, Steiner-Krammer B, Schmidt W, et al. Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates? J Craniomaxillofac Surg. 2005;33: 395-403.
31. Rodan GA, Fleisch HA. Bisphosphonates mechanisms of action. J Clin Invest. 1996;97:2692-2696.
32. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002;302:1055-1061.
33. Green JR, Rogers MJ. Pharmacologic profile of zoledronic acid: A highly potent inhibitor of bone resorption. Drug Dev Res. 2002;55:210-224.
34. Mashiba T, Mori S, Burr DB, et al. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab. 2005;23(suppl):36-42.
35. Narai S, Nagahata S. Effects of alendronate on the removal torque of implants in rats with induced osteoporosis. Int J Oral Maxillofac Implants. 2003; 18: 218-223.
36. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006;17:897-907.
37. MP Statement on Bisphosphonates. The American Academy of Periodontology Web site. Available at: http://www.perio.org/resources-products/bisphosphonates. htm. Accessed May 22, 2006.
38. Expert Panel Recommendation for the Prevention, Diagnosis and Treatment of Osteonecrosis of the Jaw. Food and Drug Administration Web site. Available at: http://www.fda.gov/ohrms/dockets/ ac/05/briefing/2005-4095B2_02_12-Novartis- Zometa-App-11.htm. Accessed May 22, 2006.
39. Katz H. Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws: A report of three cases. J Endod. 2005;31:831-834.
40. Zarychanski R, Elphee E, Walton P, et al. Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol. 2006;81:73-75.